Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis.

February 8, 2026 updated by: Mae Fah Luang University

Comparative Efficacy of Acupuncture Combined With Chinese Herbal Cream and Acupuncture Combined With Calcipotriol for Plaque Psoriasis.

Clinical trial which compares 2 treatment methods (1) Acupunture with a Chinese Herbal Cream and (2) Acupuncture with the standard treatment "calcipotriol" for patients with plaque psoriasis.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

28

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Dr.Sinee Tantasatityanon, TCMD, PhD
  • Phone Number: +66818092078
  • Email: sinee.tan@mfu.ac.th

Study Contact Backup

Study Locations

  • Thailand
    • Chiangrai
      • Muang, Chiangrai, Thailand, 57100
        • Recruiting
        • Mae Fah Luang University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Plaque psoriasis on skin, scalp, or nails
  • Not receive any psoriasis treatment at least 4 weeks prior to the study
  • ≤10% body surface area (BSA), PASI≤10, DLQI≤10

Exclusion Criteria:

  • Pregnancy and lactation
  • Other type of psoriasis i.e. Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis
  • Uncontrollable diseases i.e. CVS, liver, kidney, cancer
  • Using anticoagulants i.e. Aspirin, Warfarin, Clopidogrel, Dabigatran, Riavaraxaban, Apixaban, Heparin
  • Treated with psoriasis biologic agents in the past 6 months
  • Needle phobia
  • Receiving immunosuppresive agents i.e. systemic corticosteroid, NSAIDs, chemotherapeutic agents
  • Participating in other clinical study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Acupucture + Calcipotriol
Participant will receive 1 Acupuncture session per week for 8 weeks. And also receive Calcipotriol cream.
Procedure: Acupuncture
Bai-Hui (GV20), Fei-Shu (BL13), Ge-Shu (BL-17), Qu-Chi (LI11), Zu-San-Li (ST36), He-Gu (LI4), Tai-Chong (LR3), San-Yin-Jiao (SP6), Wei-Zhong (BL40)
Drug: Calcipotriol 0.005% ointment
Calcipotriol 0.005% ointment
Experimental: Acupuncture + Chinese Herbal Cream
Participant will receive 1 Acupuncture session per week for 8 weeks. And also receive Chinese Herbal cream.
Procedure: Acupuncture
Bai-Hui (GV20), Fei-Shu (BL13), Ge-Shu (BL-17), Qu-Chi (LI11), Zu-San-Li (ST36), He-Gu (LI4), Tai-Chong (LR3), San-Yin-Jiao (SP6), Wei-Zhong (BL40)
Drug: Chinese herb cream
Main API : Sophora flavescens Ait. (Ku-Shen), Cnidium monnieri (L.) Cuss. (She-Chuang-Zi), Prunus mume (Sieb.) Sieb.et Zucc. (Wu-Mei), Dictamnus dasycarpus Turcz. (Bai-Xian-Pi), Rheum palmatum L. (Da-Huang)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Psoriasis Area and Severity Index, PASI score
Time Frame: 8 weeks
8 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Dermatology Life Quality Index (DLQI)
Time Frame: 8 weeks
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mae Fah Luang University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 9, 2026

Primary Completion (Estimated)

February 8, 2027

Study Completion (Estimated)

February 8, 2027

Study Registration Dates

First Submitted

February 8, 2026

First Submitted That Met QC Criteria

February 8, 2026

First Posted (Actual)

February 13, 2026

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 8, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EC 25228-25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe